GlassScriptPhysician profile
Lori Schneider
NPI 1538166194
$11,681.09
in general payments reported to CMS, 2019-2025
45 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,768 · 2020: $1,257 · 2021: $1,797 · 2022: $2,133 · 2023: $1,728 · 2024: $1,673 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,426 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,426.29 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,517.50 | 2021-2025 | Ubrelvy, Qulipta |
| Biogen, INC. | $1,289.57 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Mdd US Operations, LLC | $1,241.25 | 2019-2025 | Gocovri, Apokyn, Xadago |
| Pfizer INC. | $823.46 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $619.51 | 2019-2024 | |
| Genzyme Corporation | $523.18 | 2019-2023 | |
| Neurelis, INC. | $515.10 | 2020-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $492.06 | 2019-2025 | Rytary, Crexont |
| Genentech USA, INC. | $472.26 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Teva Pharmaceuticals USA, INC. | $438.37 | 2019-2025 | Ajovy |
| Lilly USA, LLC | $380.64 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Celgene Corporation | $305.37 | 2019-2024 | Zeposia |
| Biohaven Pharmaceutical Holding Company LTD. | $273.94 | 2022 | |
| Lundbeck LLC | $264.04 | 2022-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $219.61 | 2020-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.